A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.

"Declarations Ethics approval and consent to participateAll human lymph node specimens were acquired from patients diagnosed with DLBCL and lymphoid hyperplasia at the Shanghai Ninth People’s Hospital, China, between 2019 and 2021. Informed consent was obtained from all patients, and the project was approved by the Ethics Committee of Shanghai Ninth People’s Hospital. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding The authors are grateful for support from the National Natural Science Foundation of China (Grant No. 81900145 and No.82270158), and the Science and Technology Commission of Shanghai Municipality (Grant No.21Y31920402)."